CVC Capital Partners ("CVC") today announced that funds advised by CVC have finalised the sale of part of their stake in Jintian Pharmaceutical Group Ltd ("Jintian"), a leading pharmaceutical retailer and distributor in Northeast China, which is listed on the Hong Kong Stock Exchange.
Funds advised by CVC have sold 185,500,000 shares at the price of HK$3.29 per share, and retain a stake of 6.9% in the business.
CVC funds made an initial investment in Jintian in October 2011, acquiring a 24.2% stake. The company successfully completed its listing on the Hong Kong Stock Exchange in December 2013.
Francis Leung, Managing Partner and Chairman of Greater China for CVC, commented: "We are pleased that CVC funds invested and remain invested in Jintian. The recent sale of part of the CVC funds' investment in the business is in line with our usual process of managing CVC fund investments and has realised a solid return for our investors. CVC will continue to support the management of Jintian in executing its strategic objectives."
CVC DIF agrees to acquire premier US student transportation operator ASTP from Access Holdings
CVC Credit provides financing to CapVest-backed Novus Foods through its Capital Solutions strategy
CVC DIF to acquire SBA Communications’ Canadian tower business, a leading wireless tower infrastructure platform in Canada
CVC Liquid Credit prices Cordatus XXXVI, its fifth new issue CLO of 2025
CVC Joins PAG to Partner with Australian Venue Co in New Era of Growth
CVC Liquid Credit closes H1 2025 with $7.9 billion in CLO activity across 17 Deals
CVC welcomes strategic minority partnership investment from KKR into Etraveli Group
CVC Credit provides debt facilities to smartTrade through its European Direct Lending strategy
Airalo becomes the first eSIM Unicorn with an investment round of $220m